AMIRREZA FALLAHI: Open Payments
NPI 1235766916 · BRADLEY, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$349 in 13 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $355 · 2025 $349
Food & beverage: $349
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $103 |
| Otsuka America Pharmaceutical, Inc. | 3 | $78 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| ABBVIE INC. | 1 | $28 |
| Luye Pharma (USA) Ltd. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Biogen, Inc. | 1 | $15 |
Products named: COBENFY, ABILIFY MAINTENA, AUSTEDO XR, ABILIFY ASIMTUFII, VRAYLAR, ERZOFRI EXTENDED-RELEASE, INGREZZA, REXULTI.
Industry payments across IL — which companies pay providers there.
